Anthony Marchand

Mr. Anthony Marchand

École Polytechnique Fédérale de Lausanne, Lausanne, Vaud, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Nature
Verified
Journal Article
Open access
PDF file
PGPablo Gainza
Pablo Gainza
SWSarah Wehrle
Sarah Wehrle
AHAlexandra Van Hall-Beauvais
Alexandra Van Hall-Beauvais
Anthony MarchandAnthony Marchand
Anthony Marchand
ASAndreas Scheck
Andreas Scheck
BCBruno E. Correia
Bruno E. Correia
Physical interactions between proteins are essential for most biological processes governing life1. However, the molecular determinants of such interactions have been challenging to understand, even as genomic, proteomic and structural data increase. This knowledge gap has been a major obstacle for the comprehensive understanding of cellular protein–protein interaction networks and for the de novo design of protein binders that are crucial for synthetic biology and translational applications2–9. Here we use a geometric deep-learning framework operating on protein surfaces that generates fingerprints to describe geometric and chemical features that are critical to drive protein–protein interactions10. We hypothesized that these fingerprints capture the key aspects of molecular recognition that represent a new paradigm in the computational design of novel protein interactions. As a proof of principle, we computationally designed several de novo protein binders to engage four protein targets: SARS-CoV-2 spike, PD-1, PD-L1 and CTLA-4. Several designs were experimentally optimized, whereas others were generated purely in silico, reaching nanomolar affinity with structural and mutational characterization showing highly accurate predictions. Overall, our surface-centric approach captures the physical and chemical determinants of molecular recognition, enabling an approach for the de novo design of protein interactions and, more broadly, of artificial proteins with function.

15 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
Anthony MarchandAnthony Marchand
Anthony Marchand
SBStephen Buckley
Stephen Buckley
ASArne Schneuing
Arne Schneuing
MPMartin Pacesa
Martin Pacesa
MEMaddalena Elia
Maddalena Elia
BCBruno E. Correia
Bruno E. Correia
Molecular recognition events between proteins drive biological processes in living systems1. However, higher levels of mechanistic regulation have emerged, in which protein–protein interactions are conditioned to small molecules2,3,4,5. Despite recent advances, computational tools for the design of new chemically induced protein interactions have remained a challenging task for the field6,7. Here we present a computational strategy for the design of proteins that target neosurfaces, that is, surfaces arising from protein–ligand complexes. To develop this strategy, we leveraged a geometric deep learning approach based on learned molecular surface representations8,9 and experimentally validated binders against three drug-bound protein complexes: Bcl2–venetoclax, DB3–progesterone and PDF1–actinonin. All binders demonstrated high affinities and accurate specificities, as assessed by mutational and structural characterization. Remarkably, surface fingerprints previously trained only on proteins could be applied to neosurfaces induced by interactions with small molecules, providing a powerful demonstration of generalizability that is uncommon in other deep learning approaches. We anticipate that such designed chemically induced protein interactions will have the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells for innovative drug-controlled cell-based therapies10.

8 April 2022 in Current Opinion in Structural Biology
Verified
Journal Article
Open access
Anthony MarchandAnthony Marchand
Anthony Marchand
AHAlexandra K. Van Hall-Beauvais
Alexandra K. Van Hall-Beauvais
BCBruno E. Correia
Bruno E. Correia
Protein-protein interactions (PPIs) govern numerous cellular functions in terms of signaling, transport, defense and many others. Designing novel PPIs poses a fundamental challenge to our understanding of molecular interactions. The capability to robustly engineer PPIs has immense potential for the development of novel synthetic biology tools and protein-based therapeutics. Over the last decades, many efforts in this area have relied purely on experimental approaches, but more recently, computational protein design has made important contributions. Template-based approaches utilize known PPIs and transplant the critical residues onto heterologous scaffolds. De novo design instead uses computational methods to generate novel binding motifs, allowing for a broader scope of the sites engaged in protein targets. Here, we review successful design cases, giving an overview of the methodological approaches used for templated and de novo PPI design.

30 May 2023 in ACS Chemical Biology
Verified
Journal Article
Open access
Anthony MarchandAnthony Marchand
Anthony Marchand
LBLucia Bonati
Lucia Bonati
SSSailan Shui
Sailan Shui
LSLeo Scheller
Leo Scheller
PGPablo Gainza
Pablo Gainza
BCBruno E. Correia
Bruno E. Correia
Protein-based therapeutics, such as monoclonal antibodies and cytokines, are important therapies for various pathophysiological conditions such as oncology, autoimmune disorders, and viral infections. However, the wide application of such protein therapeutics is often hindered by dose-limiting toxicities and adverse effects, namely, cytokine storm syndrome, organ failure, and others. Therefore, spatiotemporal control of the activities of these proteins is crucial to further expand their application. Here, we report the design and application of small-molecule-controlled switchable protein therapeutics by taking advantage of a previously engineered OFF-switch system. We used the Rosetta modeling suite to computationally optimize the affinity between B-cell lymphoma 2 (Bcl-2) protein and a previously developed computationally designed protein partner (LD3) to obtain a fast and efficient heterodimer disruption upon the addition of a competing drug (Venetoclax). The incorporation of the engineered OFF-switch system into anti-CTLA4, anti-HER2 antibodies, or an Fc-fused IL-15 cytokine demonstrated an efficient disruption in vitro, as well as fast clearance in vivo upon the addition of the competing drug Venetoclax. These results provide a proof-of-concept for the rational design of controllable biologics by introducing a drug-induced OFF-switch into existing protein-based therapeutics.

28 January 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PBPetra E. M. Balbi
Petra E. M. Balbi
ASAhmed Sadek
Ahmed Sadek
Anthony MarchandAnthony Marchand
Anthony Marchand
TYTa-Yi Yu
Ta-Yi Yu
JDJovan Damjanovic
Jovan Damjanovic
BCBruno E. Correia
Bruno E. Correia
The human cell surfaceome, integral to cell communication and disease mechanisms, presents a prime target for therapeutic intervention. De novo protein binder design against these cell surface proteins offers a promising yet underexplored strategy for drug development. However, the vast search space and limited data on natural or competitive binders have historically limited experimental success. In this study, we systematically analyzed the entire human surfaceome, identifying approximately 4,500 targetable sites and introducing potential binding seeds for initiating protein design applications. To validate these seeds, we implemented two experimental approaches (protein scaffolding and peptide cyclization) on three representative targets (FGFR2, IFNAR2, and HER3). Our results revealed a high success rate, showing that seeds provide valuable starting points for binder design against our identified targetable sites, as well as the need for constant improvements of computational protein design pipelines utilizing machine learning and physics-based methods. Additionally, we present SURFACE-Bind, an interactive database offering open access to all generated data. The high-throughput computational design methods and target-specific binder seeds established here pave the way for a new generation of targeted therapeutics for the human surfaceome.

27 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Anthony MarchandAnthony Marchand
Anthony Marchand
JBJoyce Van Bree
Joyce Van Bree
ATAya Taki
Aya Taki
MMMati Moyat
Mati Moyat
GTGerardo Turcatti
Gerardo Turcatti
TBTiffany Bouchery
Tiffany Bouchery
Hookworm infections cause a neglected tropical disease (NTD) affecting ~740 million people worldwide, principally those living in disadvantaged communities. Infections can cause high morbidity due to their impact on nutrient uptake and their need to feed on host blood, resulting in a loss of iron and protein, which can lead to severe anaemia and impaired cognitive development in children. Currently, only one drug, albendazole is efficient to treat hookworm infection and the scientific community fears the rise of resistant strains. As part of on-going efforts to control hookworm infections and its associated morbidities, new drugs are urgently needed. We focused on targeting the blood-feeding pathway, which is essential to the parasite survival and reproduction, using the laboratory hookworm model Nippostrongylus brasiliensis (a nematode of rodents with a similar life cycle to hookworms). We established an in vitro-drug screening assay based on a fluorescent-based measurement of parasite viability during blood-feeding to identify novel therapeutic targets. A first screen of a library of 2654 natural compounds identified four that caused decreased worm viability in a blood-feeding-dependent manner. This new screening assay has significant potential to accelerate the discovery of new drugs against hookworms.